PDCD1 and non-small cell lung carcinoma: DSP not only allowed the discovery of candidate predictive biomarkers of clinical benefit to anti-PD1 immunotherapy but also directed researchers into additional areas of investigation including the involvement of CD56+ NK and natural killer T (NKT) cells in favoring anti-tumor immune response and therapeutic efficacy within the NSCLC microenvironment [89].